Meeting
2016 ASCO Annual Meeting
Detection of minimal residual disease in FLT3/ITD AML.
Authors
Mark J. Levis
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
Mark J. Levis , Jeffrey Edward Miller , Zhiyi Xie , Valerie McClain , Andrew R. Carson , Tim Stenzel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Citation
J Clin Oncol 34, 2016 (suppl; abstr 7015)
DOI
10.1200/JCO.2016.34.15_suppl.7015
Abstract #
7015
Poster Bd #
7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Comparison of next-generation sequencing and flow cytometry in detecting minimal residual disease in adult acute lymphoid leukemia: Evaluating clinical outcomes in a single-center study.
First Author: Vinay Nittur
Poster
2018 ASCO Annual Meeting
Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.
First Author: Tapan M. Kadia
Poster
2023 ASCO Annual Meeting
Measurable residual disease (MRD) and clonal diversity for multiple myeloma treatment monitoring.
First Author: Joaquin Martinez-Lopez
Poster
2020 ASCO Virtual Scientific Program
Pre-transplant molecular minimal residual disease (MMRD) is associated with inferior outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
First Author: Muhammad Husnain